Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

HIMS Stock Plunges 10% After Hours: FDA Chief Warns Of ‘Swift Action’ On Copycat Drugs After Novo Semaglutide Knockoff Launch ↗

Topics Fraud Law Enforcement

February 05, 2026

Amazon Is Now Offering Novo Nordisk's Wegovy Pill in Its Pharmacy. Here's How That Could Affect Hims & Hers, WW International, and GoodRx Holdings. ↗

February 05, 2026

There's another fight brewing around GLP-1 drugs -- this time on the delivery side.

The Great GLP-1 Divergence: Eli Lilly Surges Toward Trillion-Dollar Dominance as Novo Nordisk Falters on U.S. Price Cuts

February 05, 2026

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a...

Via MarketMinute

Topics Earnings Economy

Novo Nordisk Threatens Legal Action Against Hims & Hers Over Compounded Wegovy Pill ↗

February 05, 2026

HIMS Stock Garners Retail Buzz After Launching New Multi-Cancer Detection Test ↗

February 04, 2026

Hims & Hers fell on fear that Novo Nordisk would take action against the company's new oral GLP-1, but there's more to the story.

Hims & Hers Takes On Novo Nordisk: What We Know Right Now ↗

February 05, 2026

Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.

Why Eli Lilly Stock Just Dropped ↗

February 05, 2026

The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.

HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling? ↗

February 05, 2026

Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*

Topics Intellectual Property

February 05, 2026

From Hims & Hers

Why Is HIMS Stock Slipping Premarket Today? ↗

January 12, 2026

Hims & Hers CEO Bets On Personalized Healthcare And AI In 2026 — Wall Street Braces For A Costly Year ↗

January 09, 2026

Hims & Hers is moving beyond prescriptions to preventative testing.

Topics Artificial Intelligence

HUGE News: Hims & Hers Adds Cancer Testing to Labs Offering ↗

February 04, 2026

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care

February 04, 2026

From Hims & Hers

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...

1 Volatile Stock for Long-Term Investors and 2 We Brush Off

February 03, 2026

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

February 02, 2026

From Hims & Hers

Shareholders of Hims & Hers Health would probably like to forget the past six months even happened. The stock dropped 57.1% and now trades at $27.15. This may have investors wondering how to approach...

Hims & Hers Health (HIMS): Buy, Sell, or Hold Post Q3 Earnings?

February 01, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare...

1 Healthcare Stock to Research Further and 2 Facing Headwinds

January 29, 2026

Netflix may be forced to offer all cash for WBD if the cable assets being spun off don't have the value Netflix thought they did. But is that something Netflix will do, and what are the risks?

Topics Stocks

Will Netflix Go All-Cash for WBD? ↗

January 29, 2026

Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over

Topics Artificial Intelligence

January 29, 2026

From Hims & Hers

When you find winning stocks, stick with them.

2 Top Stocks to Double Up On Right Now ↗

January 20, 2026

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated its Equalweight rating but voiced concerns about the company's slowing...

Topics Artificial Intelligence

Why Hims & Hers Health (HIMS) Stock Is Down Today

January 20, 2026

Nasdaq, S&P 500 Futures Wobble As Trump-Powell Clash Rattles Markets: Why CRML, HIMS, WMT, NFLX, NVAX, COF Are On Traders' Radar Today ↗

Topics Artificial Intelligence

January 12, 2026

Are you looking for investment opportunities in 2026?

Topics Stocks

Stocks to Love in 2026 ↗

January 11, 2026

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

Topics ETFs Initial Public Offering

January 05, 2026

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

1 High-Flying Stock on Our Watchlist and 2 We Question

January 04, 2026

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

As the calendar turns to 2026, the landscape for weight-loss and diabetes medication has been fundamentally transformed. What began two years ago as a "wild west" of $1,000-a-month list prices and...

Via MarketMinute

Topics Economy Intellectual Property

2 Russell 2000 Stocks Worth Investigating and 1 We Avoid

January 01, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Nasdaq Bears Dig In: Short Interest Hits Record 18.38 Billion Shares Amid Valuation Anxiety

December 24, 2025

As the final trading days of 2025 approach, the Nasdaq has reached a staggering milestone that has both bulls and bears on edge. According to the latest settlement data released on December 15, 2025,...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Hims & Hers Hit A GLP-1 Speed Bump This Year — But Growth Is Just Cooling, Not Cracking ↗

December 24, 2025

Hims & Hers has drawn scrutiny for selling compounded GLP-1 treatments – lower-cost, unapproved alternatives to blockbuster weight-loss drugs made by Eli Lilly and Novo Nordisk.